{
    "title": "Acelyrin's skin disease drug trial failure wipes off IPO gains",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12509041/Acelyrin-tumbles-skin-disease-drug-fails-meet-efficacy-bar-trial.html",
    "date": "2023-09-12",
    "keywords": [
        "acelyrin",
        "drug",
        "trial",
        "santhosh",
        "debut",
        "companys",
        "skin",
        "ipo",
        "stock",
        "value",
        "developer",
        "tuesday",
        "market",
        "superiority",
        "disease",
        "biotech",
        "year",
        "offering",
        "sector",
        "kenvue",
        "goal",
        "midtolate",
        "stage",
        "reduction",
        "hidradenitis",
        "suppurativa",
        "company",
        "hs",
        "inflammatory",
        "condition",
        "placebo",
        "efficacy",
        "sandler",
        "arthritis",
        "analyst",
        "akash",
        "tewari",
        "price",
        "target",
        "clarity",
        "path",
        "forward",
        "book",
        "ventyx",
        "bengaluru",
        "editing",
        "chakrabarty",
        "shinjini",
        "ganguli"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}